P73 mutations and expression in adult de novo acute myelogenous leukemia

Leukemia

Volumn 13, Issue 7, 1999, Pages 985-990

  Stirewalt, D L ^a   Clurman, B ^a   Appelbaum, F R ^a,b   Willman, C L ^b,c   Radich, J P ^a,b,d  

^a UNIVERSITY OF WASHINGTON   (United States)

^b SW Oncol Grp Leukemia Biol Prog ^*  (United States)

^c UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Leukemia; Myeloid; P73 gene; Tumor suppressor gene

Indexed keywords

RNA;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BONE MARROW; CELL LINE; CONTROLLED STUDY; EXON; GENE EXPRESSION; GENE MUTATION; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SYNTHESIS; SEQUENCE HOMOLOGY; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE;

EID: 0032790880     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401418     Document Type: Article

References (55)

1. Radich JP, Kopecky KJ, Willman CL, Weick J, Head D, Appelbaum F, Collins SJ. N-ras mutations in adult de novo acute myelogenous leukemia: prevalence and clinical significance. Blood 1990; 76: 801-807.
2. Neubauer A, Dodge RK, George SL, Davey FR, Silver RT, Schiffer CA, Mayer RJ, Ball ED, Wurster-Hill D, Bloomfield CD, Liu ET. Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia. Blood 1994; 83: 1603-1611.
3. Coghlan DW, Morley AA, Matthews JP, Bishop JF. The incidence and prognostic significance of mutations in codon 13 on the N-ras gene in acute myeloid leukemia. Leukemia 1994; 8: 1682-1687.
4. Arthur DC, Bloomfield CD. Partial deletion of the long arm of chromosome 16 and bone marrow eosinophilia in acute nonlymphocytic leukemia: a new association. Blood 1983; 61: 994-998.
5. Rowley ID. Recurring chromosome abnormalities in leukemia and lymphoma. Semin Hematol 1990; 27: 122-136.
6. Sakai E, Tsuchida N. Most human squamous cell carcinomas in the oral cavity contain mutated p53 tumor-suppressor genes. Oncogene 1992; 7: 927-933.
7. Nylander K, Nilsson P, Mehle C, Roos G. p53 mutations, protein expression and cell proliferation in squamous cell carcinomas of the head and neck. Br J Cancer 1995; 71: 826-830.
8. D'Amico D, Carbone D, Mitsudomi T, Nau M, Fedorko J, Russell E, Johnson B, Buchhagen D, Bodner S, Phelps R, Gazdar A, Minna JD. High frequency of somatically acquired p53 mutations in small-cell lung cancer cell lines and tumors. Oncogene 1992; 7: 339-346.
9. Fagin JA, Matsuo K, Karmakar A, Chen DL, Tang S-H, Koeffler HP. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 1993; 91: 179-184.
10. Chang F, Syrjänen S, Syränen K. Implications of the p53 tumor-suppressor gene in clinical oncology. J Clin Oncol 1995; 13: 1009-1022.
11. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323-331.
12. Felix CA, Hosler MR, Provisor D, Salhany K, Sexsmith EA, Slater DJ, Cheung NK, Winick NJ, Strauss EA, Heyn R, Lange BJ, Malkin D. The p53 gene in pediatric therapy-related leukemia and myelodysplasia. Blood 1996; 87: 4376-4381.
13. Ludwig L, Schulz AS, Janssen JWG, Grünewald K, Bartram CR. p53 mutations in myelodysplastic syndromes. Leukemia 1992; 6: 1302-1304.
14. Wattel E, Preudhomme C, Hecquet B, Vanrumbeke M, Quesnel B, Dervite I, Morel P, Fenaux P. p53 mutations are associated with resistence to chemotherapy and short survival in hematologic malignancies. Blood 1994; 84: 3148-3157.
15. Sugimoto K, Hirano N, Toyoshima H, Chiba S, Mano H, Takaku F, Yazaki Y, Hirai H. Mutations of the p53 gene in myelodysplastic syndrome (MDS) and MDS-derived leukemia. Blood 1993; 81: 3022-3026.
16. Fenaux P, Jonveaux P, Quiquandon I, Laï JL, Pignon JM, Loucheux-Lefebvre MH, Bauters F, Berger R, Kerckaert JP. P53 gene mutations in acute myeloid leukemia with 17p monosomy. Blood 1991; 78: 1652-1657.
17. Zhang W, Hu G, Estey E, Hester J, Deisseroth A. Altered conformation of the p53 protein in myeloid leukemia cells and mitogen-stimulated normal blood cells. Oncogene 1992; 7: 1645-1647.
18. Banker DE, Groudine M, Norwood T, Appelbaum FR. Measurement of spontaneous and therapeutic agent-induced apoptosis with BCL-2 protein expression in acute myeloid leukemia. Blood 1997; 89: 243-255.
19. Kaghad M, Bonnet H, Yang A, Creancler L, Biscan J-C, Valent A, Minty A, Chalon P, Lelias J-M, Durmont X, Ferrara P, McKeon F, Caput D. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other cancers. Cell 1997; 90:809-819.
20. Ross RA, Spengler BA, Domenech C, Porubcin M, Rettig WJ, Biedler JL. Human neuroblastoma I-type cells are malignant neural crest stem cells. Cell Growth Differ 1995; 6: 449-456.
21. Nagai H, Negrini M, Carter SL, Gillum DR, Rosenberg AL, Schwartz GF, Croce CM. Detection and cloning of a common region of loss of heterozygosity at chromosome 1p in breast cancer. Cancer Res 1995; 55: 1752-1757.
22. Dracopoli NC, Hamett P, Bale SJ, Stranger BZ, Tucker MA, Housman DE, Kefford RF. Loss of alleles from the distal short arm of chromosome 1 occurs late in melanoma tumor progression. Proc Natl Acad Sci USA 1989; 86: 4614-4618.
23. Clurman B, Groudine M. Killer in search of a motive? Nature 1997; 389: 122-123.
24. Jost CA, Marin MC, Kaelin WG, Jr. p73 is a human p53-related protein that can induce apoptosis (see comments). Nature 1997; 389: 191-194.
25. Mai M, Yokomizo A, Qian C, Yang P, Tindall DJ, Smith DI, Liu W. Activation of p73 silent allele in lung cancer. Cancer Res 1998; 58: 2347-2349.
26. Saiki PK, Celfand DH, Stoffel S, Scharf SJ, Higuchi R, Horn GT, Mullis KB, Erlich HA. Primer-directed enzymatic amplification of DNA with thermostable DNA polymerase. Science 1988; 239: 487-497.
27. Lee A, Kirk J, Edmands S, Radich J. Multiplex PCR of bcr-abl fusion transcripts in Philadelphia positive acute lymphoblastic leukemia. PCR Methods Appl 1995; 4: 283-287.
28. Orita M, Iwahana H, Kanazawa H, Hayashi K, Sekiya T. Detection of polymorphisms of human DNA by gel electrophoresis as single-strand confirmation polymorphisms. Proc Natl Acad Sci USA 1989; 86: 2766-2770.
29. Hongyo T, Buzard GS, Calvert RJ, Weghorst CM. 'Cold SSCP': a simple, rapid and non-radioactive method for optimized single-strand conformation polymorphism analyses. Nucleic Acids Res 1993; 21: 3637-3642.
30. Radich JP, Kopecky KJ, Appelbaum F, Willman CL, Collins SJ. N-ras mutations in acute myelogenous leukemia: a review of the current literature and an update of the Southwest Oncology Group experience. Leuk Lymphoma 1992; 6: 325-334.
31. Fourth International Workshop on Chromosomes in Leukemia. Cancer Genet Cytogenet 1984; 11: 249-360.
32. Nomoto S, Haruki N, Kondo M, Konishi H, Takahashi T. Search for mutations and examination of allelic expression imbalance of the p73 gene at 1p36.33 in human lung cancers. Cancer Res 1998; 58: 1380-1383.
33. Mai M, Huang H, Reed C, Qian C, Smith JS, Alderete B, Jenkins R, Smith DI, Liu W. Genomic organization and mutation analysis of p73 in oligodendrogliomas with chromosome 1 p-arm deletions. Genomics 1998; 51: 359-363.
34. Sunahara M, Ichimiya S, Nimura Y, Takada N, Sakiyama S, Sato Y, Todo S, Adachi W, Amano J, Nakagawara A. Mutational analysis of the p73 gene localized at chromosome 1p36.3 in colorectal carcinomas. Int J Oncol 1998; 13: 319-323.
35. Takahashi H, Ichimiya S, Nimura Y, Watanabe M, Furusato M, Wakui S, Yatani R, Aizawa S, Nakagawara A. Mutation, allelotyping, and transcription analyses of the p73 gene in prostatic carcinoma. Cancer Res 1998; 58: 2076-2077.
36. Wutz A, Smrzka OW, Schweifer N, Schellander K, Wagner EF, Barlow DP. Imprinted expression of the Igf2r gene depends on an intronic CpG island. Nature 1997; 389: 745-749.
37. Relk W, Constancia M. Making sense or antisense? Nature 1997; 389: 669-671.
38. Zhang W, Deisseroth AB. Conformational change of p53 protein in growth factor-stimulated human myelogenous leukemia cells. Leuk Lymphoma 1994; 14: 251-255.
39. Sameshima Y, Akiyama T, Mori N, Mizoguchi H, Toyoshima K, Sugimura T, Terada M, Yokota J. Point mutation of the p53 gene resulting in splicing inhibition in small cell lung carcinoma. Biochem Biophys Res Commun 1990; 173: 697-703.
40. Lai MY, Chang HC, Li HP, Ku CK, Chen PJ, Sheu JC, Huang GT, Lee PH, Chen DS. Splicing mutations of the p53 gene in human hepatocellular carcinoma. Cancer Res 1993; 53: 1653-1656.
41. Jolly KW, Malkin D, Douglass EC, Brown TF, Sinclair AE, Look AT. Splice-site mutation of the p53 gene in a family with hereditary breast-ovarian cancer. Oncogene 1994; 9: 97-102.
42. Schneider-Stock R, Oda Y, Roessner A. New splicing mutation in exon 5-6 of the p53-tumor suppressor gene in a malignant schwannoma. Hum Mutat 1997; 9: 91-94.
43. Wolf D, Rotter V. Inactivation of p53 gene expression by an insertion of Moloney murine leukemia virus-like DNA sequence. Mol Cell Biol 1984; 4: 1402-1410.
44. Mowat M, Cheng A, Kimura N, Bernstein A, Benchimo S. Rearrangements of the cellular p53 gene in erythroleukaemic cells transformed by Friend virus. Nature 1985; 314: 633-636.
45. Szekely L, Selivanova G, Magnusson KP, Klein G, Wiman KG. EBNA-5, and Epstein-Barr virus-encoded nuclear antigen, binds to the retinoblastoma and p53. Proc Natl Acad Sci USA 1993; 90: 5455-5459.
46. Sarnow P, Ho YS, Williams J, Levine AJ. Adenovirus Elb-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells. Cell 1982; 28: 387-394.
47. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992; 358: 80-83.
48. Leach FS, Tokino T, Meltzer P, Burrell M, Oliner JD, Smith S, Hill DE, Sidransky D, Kinzler KW, Vogelstein B. p53 mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 1993; 53: 2231-2234.
49. Sheikh MS, Shao Z-m, Hussain A, Fontana J. The p53-binding protein MDM2 gene is differentially expressed in human breast carcinoma. Cancer Res 1993; 53: 3226-3228.
50. Bueso-Ramos CE, Yang Y, deLeon E, McCown P, Stass SA, Albitar M. The human MDM-2 oncogene is overexpressed in leukemias. Blood 1993; 82: 2617-2623.
51. Zion M, Ben-Yehuda D, Avraham A, Cohen O, Wetzler M, Melloul D, Ben-Neriah Y. Progressive de novo DNA methylation at the bcr-abl locus in the course of chronic myelogenous leukemia. Proc Natl Acad Sci USA 1994; 91: 10722-10726.
52. Litz CE, Vos JA, Copenhaver CM. Aberrant methylation of the major breakpoint cluster region in chronic myeloid leukemia. Blood 1996; 88: 2241-2249.
53. Wu H-K, Weksberg R, Minden MD, Squire JA. Loss of imprinting of human insulin-like growth factor II gene, IGF2, in acute myeloid leukemia. Biochem Biophys Res Commun 1997; 231: 466-472.
54. Randhawa GS, Cui H, Barletta JA, Strichman-Almashanu LZ, Talpaz M, Kantarjian H, Deisseroth AB, Champlin RC, Feinberg AP. Loss of imprinting in disease progression in chronic myelogeous leukemia. Blood 1998; 91: 3144-3147.
55. Kip1 is haplo-insufficient for tumor suppression. Nature 1998; 396: 177-180.